# Data Sheet (Cat.No.T12079)



## ML604440

# **Chemical Properties**


CAS No.: 1140517-08-3

Formula: C17H24BF3N2O4

Molecular Weight: 388.19

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



# **Biological Description**

Description	ML604440 is a cell permeable proteasome β1i (LMP2) subunit inhibitor.	NO!
Targets(IC50)	Proteasome	

## **Solubility Information**

Solubility	DMSO: 100 mg/mL (257.61 mM),Sonication is recommended.
	(< 1 mg/ml refers to the product slightly soluble or insoluble)

#### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5761 mL	12.8803 mL	25.7606 mL
5 mM	0.5152 mL	2.5761 mL	5.1521 mL
10 mM	0.2576 mL	1.288 mL	2.5761 mL
50 mM	0.0515 mL	0.2576 mL	0.5152 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

de Bruin G, et al. Structure-based design of  $\beta$ 1i or  $\beta$ 5i specific inhibitors of human immunoproteasomes. J Med Chem. 2014 Jul 24;57(14):6197-209

Chen X, Chen Y, Ou Y, et al. Bortezomib inhibits NLRP3 inflammasome activation and NF-kB pathway to reduce psoriatic inflammation. Biochemical Pharmacology. 2022, 206: 115326.

Basler M, et al. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep. 2018 Dec;19(12). pii: e46512.

Page 1 of 2 www.targetmol.com

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com